BeOne Medicines (6160) Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6160 from our risk checks.
6160 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BeOne Medicines AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$193.70 |
| 52 Week High | US$229.40 |
| 52 Week Low | US$103.10 |
| Beta | 0.46 |
| 1 Month Change | 1.73% |
| 3 Month Change | -7.76% |
| 1 Year Change | 57.22% |
| 3 Year Change | 59.69% |
| 5 Year Change | 43.48% |
| Change since IPO | 81.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6160 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.9% | -2.1% | 0.3% |
| 1Y | 57.2% | 110.2% | 32.2% |
Return vs Industry: 6160 underperformed the Hong Kong Biotechs industry which returned 110.2% over the past year.
Return vs Market: 6160 exceeded the Hong Kong Market which returned 32.2% over the past year.
Price Volatility
| 6160 volatility | |
|---|---|
| 6160 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.4% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 6160 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6160's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 11,000 | John Oyler | beonemedicines.com |
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
BeOne Medicines AG Fundamentals Summary
| 6160 fundamental statistics | |
|---|---|
| Market cap | HK$278.00b |
| Earnings (TTM) | HK$533.34m |
| Revenue (TTM) | HK$38.69b |
Is 6160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6160 income statement (TTM) | |
|---|---|
| Revenue | US$4.97b |
| Cost of Revenue | US$686.68m |
| Gross Profit | US$4.29b |
| Other Expenses | US$4.22b |
| Earnings | US$68.55m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 86.19% |
| Net Profit Margin | 1.38% |
| Debt/Equity Ratio | 23.1% |
How did 6160 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 19:38 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BeOne Medicines AG is covered by 67 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tianli Wen | Aletheia Analyst Network Limited |
| Brian Skorney | Baird |
| Peter Lawson | Barclays |